Testing azole pills for recurring brain tumors after surgery
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This early-phase study tests whether certain anti-fungal “azole” pills can help control recurring high-grade gliomas (a type of aggressive brain tumor) after the tumor comes back. It’s meant for adults whose medical team believes the recurrence is real tumor growth and who may need another surgical procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older
- Your tumor must be a true recurrence (not “pseudoprogression”) and your team must feel it would be treated with surgery
- You need to be well enough to function: Karnofsky score 60% or higher and ECOG 2 or lower
- You must have enough time to participate: life expectancy over 12 weeks
- Your blood tests must show healthy liver and kidney function (and certain salts/electrolytes in the normal range, like potassium/calcium/magnesium)
- You must be able to swallow pills and agree to study safety rules, including pregnancy prevention if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests letrozole, a hormone-blocking medicine, in adults with recurrent high-grade gliomas. The goal is to see if it can help control the tumor and is safe enough to study further.
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
This Phase 2 study tests ERC1671 together with four other medicines to treat recurrent or worsening glioblastoma (a WHO grade IV brain cancer). It aims to slow tumor growth and improve outcomes after the tumor comes back.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This Phase 2 study tests whether adding recombinant human endostatin to temozolomide and irinotecan can slow or control recurrent gliomas (brain tumors) after prior standard treatment. It may help by targeting tumor blood vessel growth while also using chemotherapy to attack cancer cells.
Hear when a new Brain Tumor, Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.